Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.

European journal of cancer (Oxford, England : 1990) - 1 Jun 2011

Sonnemann Jürgen, Palani Chithra D, Wittig Susan, Becker Sabine, Eichhorn Friederike, Voigt Astrid, Beck James F

Abstract excerpt

Mutation of p53 is rare in Ewing's sarcoma (ES), suggesting that targeting and activation of wild-type p53 may be an effective therapeutic strategy for ES. The recently developed small-molecule MDM2 inhibitor nutlin-3 restores wild-type p53 function, resulting in the inhibition of cancer cell growth and the induction of apoptosis. In the present study, we explored the responsiveness of ES cell lines with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, p53
Share to Cellular Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Membrane Potential, Mitochondrial

Share to Membrane Potentials

Share to NF-kappa B

Share to Piperazines

Share to Sarcoma, Ewing

Source

Identifiers

PMID: 21334198
DOI: 10.1016/j.ejca.2011.01.015

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.PMID 21334198Read ↗

Nutlin-3a Is a Potential Therapeutic for Ewing SarcomaSemantic proximity Read ↗

RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.Semantic proximity Read ↗

Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.Semantic proximity Read ↗

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cellsSemantic proximity Read ↗

Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma CellsSemantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.Semantic proximity Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.Semantic proximity Read ↗

Targeting the p53 Pathway in Ewing SarcomaSemantic proximity Read ↗

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapySemantic proximity Read ↗

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.